The risk factor involves a modification (DNA methylation) to the BRCA1 gene. BRCA1 is known for its involvement in breast and ovarian cancer. Women with mutations in this gene, which inactivates its function, are predisposed to these diseases.

The DNA methylation modification is known as an epimutation and acts to turn off the BRCA1 gene from its normal protective function against breast cancer. It is not considered a genetic mutation as it does not directly affect the sequence of the gene like a mutation but nevertheless inactivates the normal protective function of the gene.

The study involved women diagnosed with breast cancer before the age of 40 years for whom BRCA1 mutations had not been identified. The epimutation was found in the blood of some women with breast cancer, especially those who develop the same type of breast cancer that develops in women with a BRCA1 mutation. However, unlike mutations in the BRCA1 gene, these epimutations appear not to be inherited and the relatives of women with epimutations are not at increased risk of breast or ovarian cancer.

Professor Melissa Southey from the University of Melbourne Department of Pathology, co-leader of the Australian Breast Cancer Family Study and a senior author on the paper said factors that triggered epimutations that stopped the gene BRCA1 from doing its usual job of preventing breast cancer might cause the same proportion of early-onset breast cancers (10%) as do inherited faults in this gene.

"For about 3-4% of young women, their BRCA1 gene has been made less capable of preventing breast cancers by some unknown factors. This places them at a 3.5-fold increased risk of breast cancer. This discovery of this modification in BRCA1 gene provides impetus for further work in this area," she said.

Associate Professor Alexander Dobrovic from the Pathology Department of the Peter MacCallum Cancer Centre and the lead investigator on this collaborative study said that the discovery of this epimutation in the peripheral blood indicated that it was present in many tissues of the body.

"This is highly significant for the understanding of mechanisms of breast cancer development as it could drive the development of breast cancer in the same way as a mutation. Many questions remain unanswered, in particular what triggers this epimutation and whether women carrying this risk factor can reduce their risk by dietary or pharmacological intervention."

Testing for this risk factor will be unavailable until answers to these and other questions are known.

The research team comprises Dr. Ee Ming Wong, Professor Stephen Fox and Associate Professor Alexander Dobrovic of the Department of Pathology of the Peter MacCallum Cancer Centre; Associate Professor Melissa Southey of the Department of Pathology, The University of Melbourne: Professor John Hopper and Dr. James Dowty of the Centre for Molecular, Environmental, Genetic and Analytical Epidemiology, The University of Melbourne; Professor Melissa Brown, School of Chemistry and Molecular Biosciences, The University of Queensland, and Professor Graham Giles and Associate Professor Mark Jenkins of the Cancer Epidemiology Centre of The Cancer Council of Victoria.

The research has been funded by the United States Department of Defense and National Institutes of Health, the Cancer Council of Victoria, the National Health and Medical Research Council of Australia, Susan G. Komen for the Cure and the National Breast Cancer Foundation of Australia.

Note: If no author is given, the source is cited instead.

• Breast Cancer
• Cancer
• Women's Health
• Ovarian Cancer
• Colon Cancer
• Diseases and Conditions

• BRCA1
• BRCA2
• Tumor suppressor gene
• Breast cancer
• Mutation
• Breast reconstruction